About Adaptimmune
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer.
Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.
We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.
|
|
|
201-500 employees
View all Adaptimmune employees
|
|
Biotechnology
|
|
60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, GB
|
|
2008
|
Adaptimmune Alternatives
Frequently Asked Questions about Adaptimmune
Adrian Rawcliffe is the CEO of Adaptimmune. To contact Adrian Rawcliffe email at [email protected] or [email protected].
The decision makers in Adaptimmune are Adrian Rawcliffe, Christopher Evans, Eric Dollins, etc. Click to Find Adaptimmune decision makers emails.
Adaptimmune Staff Directory
Search Adaptimmune Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
